Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-3,708
Closed -$1.12M 315
2018
Q4
$1.12M Buy
3,708
+1,000
+37% +$319K 0.04% 166
2018
Q3
$957K Buy
2,708
+1,975
+269% +$680K 0.03% 182
2018
Q2
$213K Sell
733
-130
-15% -$36.5K 0.01% 275
2018
Q1
$236K Sell
863
-60,150
-99% -$18.7M 0.01% 272
2017
Q4
$19.4M Buy
61,013
+60,100
+6,583% +$19.3M 0.79% 47
2017
Q3
$286K Sell
913
-69
-7% -$20.4K 0.01% 251
2017
Q2
$266K Hold
982
0.01% 254
2017
Q1
$268K Sell
982
-378
-28% -$107K 0.01% 258
2016
Q4
$386K Sell
1,360
-17
-1% -$5.04K 0.02% 224
2016
Q3
$431K Sell
1,377
-25
-2% -$7.4K 0.02% 215
2016
Q2
$339K Buy
1,402
+25
+2% +$6.59K 0.02% 225
2016
Q1
$358K Hold
1,377
0.02% 216
2015
Q4
$386K Buy
1,377
+3
+0.2% +$862 0.02% 213
2015
Q3
$401K Buy
1,374
+35
+3% +$11.6K 0.03% 214
2015
Q2
$541K Buy
1,339
+114
+9% +$45.8K 0.04% 196
2015
Q1
$517K Sell
1,225
-720
-37% -$284K 0.03% 202
2014
Q4
$660K Sell
1,945
-76
-4% -$24.6K 0.04% 185
2014
Q3
$669K Sell
2,021
-970
-32% -$320K 0.05% 177
2014
Q2
$943K Buy
2,991
+150
+5% +$45.1K 0.07% 146
2014
Q1
$869K Buy
+2,841
New +$902K 0.07% 152
2013
Q4
Sell
-953
Closed -$229K 219
2013
Q3
$229K Hold
953
0.03% 230
2013
Q2
$205K Buy
+953
New +$204K 0.03% 220

Other funds holding BIIB

Rathbones Group's BIIB Position: Q1 2019 in Review

Rathbones Group sold out of Biogen (BIIB) in Q1 2019, closing a stake of 3,708 shares — an estimated $1.12M sold.

Rathbones Group first reported a position in BIIB in Q2 2013 and held it in 22 quarters. The position peaked at $19.4M in Q4 2017. 1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

  • Rathbones Group reported no remaining Biogen position as of Q1 2019 after selling out during the quarter.
  • Rathbones Group sold 3,708 Biogen shares in Q1 2019, an estimated $1.12M.
  • Rathbones Group first reported a position in Biogen in Q2 2013 and held it in 22 quarters.
  • Rathbones Group's Biogen position peaked at $19.4M in Q4 2017.
  • 1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on Rathbones Group's 13F filing for Q1 2019, filed 9 May 2019.